BR112023027401A2 - Antígenos do vírus influenza - Google Patents

Antígenos do vírus influenza

Info

Publication number
BR112023027401A2
BR112023027401A2 BR112023027401A BR112023027401A BR112023027401A2 BR 112023027401 A2 BR112023027401 A2 BR 112023027401A2 BR 112023027401 A BR112023027401 A BR 112023027401A BR 112023027401 A BR112023027401 A BR 112023027401A BR 112023027401 A2 BR112023027401 A2 BR 112023027401A2
Authority
BR
Brazil
Prior art keywords
antigens
influenza virus
virus antigens
influenza
polynucleotides
Prior art date
Application number
BR112023027401A
Other languages
English (en)
Inventor
Lionel Sacconnay
Normand Blais
Bojidarov Vassilev Ventzislav
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2116787.9A external-priority patent/GB202116787D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112023027401A2 publication Critical patent/BR112023027401A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

antígenos do vírus influenza. a presente invenção refere-se a antígenos de hemaglutinina da cepa do vírus influenza b recombinante, polinucleotídeos que codificam os antígenos e composições imunogênicas compreendendo os antígenos e os polinucleotídeos.
BR112023027401A 2021-06-28 2022-06-24 Antígenos do vírus influenza BR112023027401A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21182184 2021-06-28
GBGB2116787.9A GB202116787D0 (en) 2021-11-22 2021-11-22 Novel influenza antigens
PCT/EP2022/067299 WO2023274860A1 (en) 2021-06-28 2022-06-24 Novel influenza antigens

Publications (1)

Publication Number Publication Date
BR112023027401A2 true BR112023027401A2 (pt) 2024-03-12

Family

ID=82399295

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023027401A BR112023027401A2 (pt) 2021-06-28 2022-06-24 Antígenos do vírus influenza

Country Status (3)

Country Link
BR (1) BR112023027401A2 (pt)
CA (1) CA3222568A1 (pt)
WO (1) WO2023274860A1 (pt)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
EP1861122A1 (en) 2005-03-23 2007-12-05 GlaxoSmithKline Biologicals S.A. Composition
CN102939103A (zh) * 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
GB201009676D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
GB201009673D0 (en) 2010-06-10 2010-07-21 Glaxosmithkline Biolog Sa Novel process
CA2849822C (en) 2011-09-23 2021-05-11 Gary J. Nabel, M.D. Novel influenza hemagglutinin protein-based vaccines
IN2014CN04742A (pt) * 2011-11-28 2015-09-18 Crucell Holland Bv
PT3148578T (pt) 2014-05-27 2022-08-23 Us Health Trímeros estabilizados da região do caule da hemaglutinina do vírus da gripe e suas utilizações
GB201603625D0 (en) 2016-03-02 2016-04-13 Glaxosmithkline Biolog Sa Novel influenza antigens
EP3506938A1 (en) 2016-09-02 2019-07-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
EP3917567A1 (en) 2019-01-30 2021-12-08 GlaxoSmithKline Biologicals SA Oil/surfactant mixtures for self-emulsification

Also Published As

Publication number Publication date
CA3222568A1 (en) 2023-01-05
WO2023274860A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
BR112023000323A2 (pt) Vacina combinada contra sars-cov-2 e influenza
CL2019002196A1 (es) Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610)
PH12017501216A1 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
CL2011002354A1 (es) Composicion inmunogenica que permite aumentar una respuesta inmunitaria contra el virus de la influenza, que comprende glicoproteina hemaglutinina de las cepas de influenza h1, h3 o h5 parcialmente glicosilada en al menos un sitio de glicosilacion, donde el sitio parcialmente glicosilado comprende una mono-, una di- o una tri-glicosilacion.
CR20110084A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos
CY1114762T1 (el) Εμβολιασμος με πολλαπλους κλαδους του ιου της γριπης η5 α
CL2022000563A1 (es) Desarrollo de una vacuna novedosa atenuada viva contra la peste porcina africana basada en la eliminación del gen i177l.
AR121361A1 (es) Vacuna
BR112016022113A2 (pt) anticorpos anti-hemaglutinina do vírus influenza b e métodos de uso
WO2019246363A8 (en) Mosaic influenza virus hemagglutinin polypeptides and uses thereof
EA201991377A1 (ru) Композиции универсальной вакцины против гриппа
WO2016196846A3 (en) Engineered influenza antigenic polypeptides and immunogenic compositions thereof
BR112018010679A2 (pt) métodos para tratar, prevenir e diagnosticar a infecção por vírus da diarréia epidêmica porcina
PL408649A1 (pl) Białko hemaglutyniny wirusów grypy jako antygen szczepionkowy
BR112021020907A2 (pt) Antígenos de influenza recombinantes
CL2007000526A1 (es) Antigeno vacunal quimerico contra el virus de la influenza aviar, ia, que contiene el segmento extracelular de la hemaglutinina de la envoltura del virus de ia y el segmento extracelular de la proteina cd154; y composicion que lo comprende.
BR112023005043A2 (pt) Vacina contra covid-19 à base de piv5
BR112017000640A2 (pt) anticorpos neutralizantes do vírus influenza b e suas utilizações
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
BR112023027401A2 (pt) Antígenos do vírus influenza
CO2023015036A2 (es) Composición inmunogénica contra la influenza
BR112018015912A2 (pt) vírus da vacina da síndrome respiratória e reprodutiva porcina
CO2020000021A2 (es) Método para preparar reserva de cepas víricas de trabajo para la influenza, método para preparar la vacuna contra la influenza usando la misma reserva de cepas, y la reserva de cepas víricas preparadas por el mismo método
BR112020010202A8 (pt) Cepa para vacina de influenza aviária h9 que diferencia animais infectados de vacinados, e método de preparação para a mesma
BR112023023671A2 (pt) Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos